SYH2082 / CSPC Pharma, AstraZeneca - LARVOL DELTA

GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection (SYH208 injection) obtains clinical trial approval in China (HKEXnews) - "The indication for the approved clinical trial is weight management for individuals with obesity or overweight and at least one weight-related comorbidity."

New trial • Obesity

SPC Pharmaceutical Group Limited…is pleased to announce that the Group has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. with GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection (SYH2082 Injection) developed by the Group (HKEXnews) - "The indication for the approved clinical trial is weight management for individuals with obesity or overweight and at least one weight-related comorbidity."

IND • Obesity

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals (AstraZeneca Press Release) - "AstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and three preclinical programmes with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions...The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory clearances...Under the agreement, CSPC will progress ongoing development of the four programmes through Phase I completion, alongside the four new programmes."

Licensing / partnership • Obesity